Monoclonal TCR-redirected tumor cell killing-Reference-Cited by-同舟云学术

Monoclonal TCR-redirected tumor cell killing

Published:2012-05-06 Issue:6 Volume:18 Page:980-987
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Liddy Nathaniel,Bossi Giovanna,Adams Katherine J,Lissina Anna,Mahon Tara M,Hassan Namir J,Gavarret Jessie,Bianchi Frayne C,Pumphrey Nicholas J,Ladell Kristin,Gostick Emma,Sewell Andrew K,Lissin Nikolai M,Harwood Naomi E,Molloy Peter E,Li Yi,Cameron Brian J,Sami Malkit,Baston Emma E,Todorov Penio T,Paston Samantha J,Dennis Rebecca E,Harper Jane V,Dunn Steve M,Ashfield Rebecca,Johnson Andy,McGrath Yvonne,Plesa Gabriela,June Carl H,Kalos Michael,Price David A,Vuidepot Annelise,Williams Daniel D,Sutton Deborah H,Jakobsen Bent K

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.2764.pdf

Reference40 articles.

1. Köhler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).

2. Isaacs, J.D. et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340, 748–752 (1992).

3. Maynard, J. & Georgiou, G. Antibody engineering. Annu. Rev. Biomed. Eng. 2, 339–376 (2000).

4. Kufer, P., Lutterbuse, R. & Baeuerle, P.A. A revival of bispecific antibodies. Trends Biotechnol. 22, 238–244 (2004).

5. Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443–446 (2000).

Cited by 255 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Escherichia coli in the production of biopharmaceuticals;Biotechnology and Applied Biochemistry;2024-09-08

2. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors;International Immunopharmacology;2024-09

3. Engineering Mesoscale T Cell Receptor Clustering by Plug‐and‐Play Nanotools;Advanced Materials;2024-08-27

4. Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment;Annual Review of Chemical and Biomolecular Engineering;2024-07-24

5. First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC;Expert Review of Anticancer Therapy;2024-07-10